<DOC>
	<DOCNO>NCT00568464</DOCNO>
	<brief_summary>The purpose clinical trial evaluate efficacy tolerability sequential therapy VCD/IE patient ESFT .</brief_summary>
	<brief_title>Study VCD/IE Patients With Ewing 's Sarcoma Family Tumors ( ESFT )</brief_title>
	<detailed_description>80-90 % patient ESFT develope disease progression period local treatment ( surgery radiation ) . The survival improve 30 year due chemotherapy . VCD/IE widely use world patient ESFT , rarely used China due high dosage .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<criteria>Age range 1065 year old Histological confirm ESFT No previous therapy ECOG performance status le 2 Life expectancy 12 week Normal laboratory value : hemoglobin &gt; 8.0g/dl , neutrophil &gt; 2×109/L , platelet &gt; 80×109/L , Hb &gt; 80×1012/L , serum creatine &lt; 1×upper limitation normal ( ULN ) , serum bilirubin &lt; 1.5×ULN , ALT AST &lt; 2.5×ULN Pregnant lactate woman Received treatment disease previously Serious uncontrolled disease intercurrent infection The evidence CNS metastasis bone marrow involvement History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix History allergy drug trial Abnormal LVEF level</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>ESFT ( Ewing 's sarcoma family tumor )</keyword>
	<keyword>Response rate</keyword>
	<keyword>TTP</keyword>
	<keyword>OS</keyword>
	<keyword>Toxicity</keyword>
</DOC>